Biogen Idec (BIIB +2.8%) on a mixed Q4 report, missing on its bottom line but slightly beating...

|About: Biogen Inc. (BIIB)|By:, SA News Editor

Biogen Idec (BIIB +2.8%) on a mixed Q4 report, missing on its bottom line but slightly beating on revenue. Net earnings actually fell 2.7% Y/Y, due largely to the company's preparations to launch its new multiple sclerosis drug BG-12, which masked revenue growth from its existing MS treatment. The company also boosted its FY13 revenue growth expectations to 10%. Analysts are looking for a 9% rise to $5.98B.